So, when you asked me the challenges, imagine we have practices that paid $40 million in DIR fees. We have a specialty pharmacy that paid 100 million, and Caremark says they give essentially a report card that tells you adherence, but they don't tell you how they arrived at that, they don't tell you their methodology, and they don't tell you which patients they think were not adherent. So administratively a challenge is no practice here other than 14 practices that have a Caremark DIR fee arbitration has any idea how Caremark actually judges there MPR. Or in other words, which patients were not adherent in the eyes of Caremark. So, one administrative challenge is a lack of transparency. But there are other administrative challenges.